ADCC Biospectrum

Our new ADCC Biospectrum for assessment of ADCC is tailored to your needs for extremely sensitive and biologically relevant results. The ADCC Biospectrum offers a fast, cost effective and reliable assessment of biosimilarity using:

  • Genotyped donors
  • Multiple effector cell preparations
  • Disease state effector cell options
  • Biologically relevant matrix formulations
  • Extreme sensitivity to various glycan species

Designed to augment traditional ADCC methods, the ADCC Biospectrum utilises innovative techniques to detect clinically relevant differences between innovator and biosimilar drugs. Our assays support fingerprint-like similarity assessments, delivering highly sensitive and quality results.

Ask our experts

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy